The association between adverse pregnancy outcomes and the serum inhibin A levels in mid-trimester of gestation.
- Author:
Hyon Myong OH
1
;
Suk Young KIM
;
Soon Pyo LEE
;
You Kyoung SOHN
;
Gyoung Hoon LEE
;
Jeong Min KIM
Author Information
1. Department of Obstetric and Gynecology, Gachon University of Medicine and Science, Incheon, Korea. ksyob@gilhospital.com
- Publication Type:Original Article
- Keywords:
Quad test;
Inhibin-A;
Preeclampsia;
Fetal loss
- MeSH:
Adenine;
Biomarkers;
Carbamates;
Deoxycytidine;
Drug Combinations;
Female;
Fetal Death;
Fetal Development;
Humans;
Hypertension, Pregnancy-Induced;
Incidence;
Inhibins;
Organophosphonates;
Pre-Eclampsia;
Pregnancy;
Pregnancy Outcome;
Pregnancy Trimester, Second;
Premature Birth;
Quinolones;
Thiazoles;
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- From:Korean Journal of Obstetrics and Gynecology
2008;51(11):1239-1244
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: To investigate the association between abnormal inhibin-A level in Quad test during the 15 and 18 weeks of gestation and adverse pregnancy outcomes. METHODS: From January 2005 to March 2007, women who delivered their babies at our institute after Quad test in second trimester of gestation (N=140) were enrolled. We measured inhibin-A levels (MoM) and other serum markers of the Quad test. And we analyzed the incidence of adverse pregnancy outcomes such as preterm birth, fetal growth restriction, pregnancy induced hypertension, fetal loss, and intrauterine fetal death. RESULTS: When the pregnancy outcomes are hypertensive disorders and fetal losses, the inhibin-A levels are is more elevated with statistically significance. Inhibin-A and hCG levels are elevated with significantly at hypertensive disorders and fetal losses. But inhibin-A levels are more significantly associated with abnormal pregnancy outcomes than hCG. CONCLUSIONS: Measurement of inhibin-A levels may be the most useful among other serum markers of the Quad test in predicting adverse obstetric outcomes.
